


Title: Management of Submission of Research Study Protocol and Study Related Documents


SOP Code: SOP 06/v2

Effective Date: 01/08/2016


Prepared by:

Dr. Uma Kulkarni Jt Secretary, YUEC	Signature with date  30/07/2016
--	---


Reviewed by

Dr. Vina Vaswani Member-Secretary, YUEC	Signature with date  30/7/2016
--	--

Approved by:

Dr. Sayeegeetha Hegde Chairperson, YUEC	Signature with date  3/8/16
--	---

Notified by:

Registrar, Yenepoya University vide notification no. YUREG/ACA/YUEC/FERCAP/01/2016	Signature with date  01/8/16 Dr. G. Shree Kumar Menon Registrar
--	---

Yenepoya University
Mangaluru - 675 018

Title: Management of Submission of Research Study Protocol and Study Related Documents

SOP Code: SOP 06/v2

Effective Date: 01/08/2016

Prepared by:

Dr. Uma Kulkarni Jt Secretary, YEC-1	Signature with date
---	---------------------

Reviewed by

Dr. Vina Vaswani Member-Secretary, YEC-1	Signature with date
---	---------------------

Approved by:

Dr. Sayeegeetha Hegde Chairperson, YEC-1	Signature with date
---	---------------------

Notified by:

Registrar, Yenepoya deemed to be University vide notification no. YU/REG/ACA/YEC- 1/FERCAP/01/2016 dated 01/08/2016	Signature with date
---	---------------------

Table of Contents:

Sl No	Content	Page
1	Purpose	3
2	Scope	3
3	Responsibility	3
4	Detailed instructions	4
5	References to other SOPs	10
6	Annexures	11
7	Flowchart	31

1. Purpose:

The purpose of this Standard Operating Procedure (SOP) is to describe how the Secretariat of the Yenepoya Ethics Committee - 1 (YEC-1) manages submissions of study protocols and other study related documents.

2. Scope:

The scope of this SOP includes:

- Submission of study protocol and related documents for initial review of the protocol
- Resubmission of protocols
- Submission of protocol amendments
- Submission of written communications related to
- Continuing review of approved protocols
- Protocol completion or termination or status
- Protocol deviations/violation
- Serious adverse events initial report/follow up/final report

3. Responsibility:

3.1 YEC-1 Secretariat:

- 3.1.1 The YEC-1 Secretariat will be responsible for receiving the protocols and related documents submitted to the YEC-1.
- 3.1.2 At the time of submission, the Secretariat will check the protocols for completeness as per the standard checklist (Ann2A/SOP06/v2; Ann2B/SOP06/v2) before accepting it.
- 3.1.3 The Secretariat will record the important details of submission in the entry log book which includes name, department and institution of the PI, date of application, date of clearance from the Scientific Review Board (if applicable) and the date of submission to YEC-1.
- 3.1.4 The YEC-1 Secretariat will ask the Principal Investigator to submit the soft copy by email (after making modifications as advised by the scientific review board) to ethcom@yenepoya.edu.in.
- 3.1.5 The YEC-1 Secretariat will present the protocols to the YEC-1 Member-Secretary/Jt Secretary for categorization for initial review and allocation of reviewers.

- 3.1.6 YEC-1 Secretariat will distribute the protocols to the reviewers as identified by the Member-Secretary by email or hard copy (as applicable for individual reviewers).
- 3.1.7 YEC-1 Secretariat will receive the reviewers' response and act according to the report as follows:
 - 3.1.7.1 If the reviewer suggests modifications in the protocol, the Secretariat will, in consultation with the Member-Secretary, communicate the same with the investigator via email.
 - 3.1.7.2 If the reviewer approves the protocol, the same will be communicated to the Member-Secretary.
- 3.1.8 YEC-1 Secretariat will enter the details of the protocol in the database of the YEC-1 Secretariat computer and update the details as the process of review is happening.
- 3.1.9 If the reviewer does not respond with the review report within 7 calendar days after sending the proposal for review, the Secretariat will send them a reminder.

3.2 The Member-Secretary/Jt Secretary:

- 3.2.1 Upon receiving the protocol for initial review, the Member-Secretary/Jt Secretary will allocate the primary and if necessary, the secondary reviewer based on the subject of research and the expertise of the reviewers
- 3.2.2 Upon receiving other protocols or related documents for review the Member-Secretary/Jt Secretary will be responsible for managing the reviews as per various SOP and the timeframes.
- 3.2.3 The Member-Secretary/Jt Secretary will be responsible for assigning the reviewers for each protocol

4. Detailed instructions:

- 4.1 **Decision making and timing:** When the Principal Investigator (PI) submits a research proposal to the YEC-1 Secretariat for review, the decision under any of the following sections will be taken within the specified time period:
 - 4.1.1 **New Proposals for Initial Review/ Re-submission of Protocols with Corrections/ Amended Protocols (and related documents):**

- 4.1.1.1 In the case of regulated clinical trials, the protocol, complete in all documentation, submitted at least 28 calendar days prior to the forthcoming YEC-1 meeting, will be reviewed and included for discussion under the category of full review. In the case of all other protocols classified for “full review” or “expedited review” or “exempt from review”, completed documentation should be submitted at least 14 calendar days prior to the date of the forthcoming YEC-1 meeting. The meeting dates for the calendar year will be put up on the website of the University (www.yenepoya.edu.in) and the Centre for Ethics (www.ethics.edu.in).
- 4.1.1.2 **Submission of SAE (On-Site):** The SAEs will be reviewed and forwarded to the SAE subcommittee on an urgent basis as per the timelines stated in SOP09/v2 for initial and detailed reporting of SAE.
- 4.1.1.3 **Resubmissions for full review:** Resubmission documents which are for consideration at the full review of the YEC-1 meeting must be submitted to YEC-1 Secretariat, at least 7 calendar days prior to the date of the forthcoming meeting.
- 4.1.1.4 **Other documents:** All other communications to the YEC-1 that need to be tabled in the agenda should reach YEC-1 Secretariat, at least 3 calendar days prior to the date of the forthcoming meeting.
- 4.1.2 **Initial review application:**
- 4.1.2.1 **Check for submission items:** The Secretariat will check the hard and soft copies of the following items:
- One hard copy set of the research protocol (after making all the necessary changes as suggested by the respective scientific review boards) to be submitted to the YEC-1 Secretariat.
 - The soft copy of the research protocol (after making all the necessary changes as suggested by the respective scientific review boards) to be sent by email to ethcom@yenepoya.edu.in from the email id of the principal investigator.

- A completely filled YEC-1 Project Submission Application Form for Initial Review (Ann1A/SOP06/v2 for regulated clinical trials or Ann1B/SOP06/v2 for non-regulated academic trials)
- The marked checklist (Ann2A/SOP06/v2 in case of regulated clinical trials and Ann2B/SOP06/v2 in case of non-regulated academic trials) (*also available on the website www.ethics.edu.in*)
- Duty Delegation Log of the Study team (Ann03/SOP06/v2)

4.1.2.2 **Verify contents of the submitted documents:**

The Secretariat will use the checklist (Ann2A or 2B/SOP06/v2) to confirm whether all the ticked documents are present in the application. The Secretariat will ensure that the application is complete in terms of required documents (if any essential document is not available an explanation must be sought in writing for the YEC-1 to review). All the following documents must be in the file before it is sent out to the reviewers for ethical review:

- Covering letter to Member-Secretary/Chairperson (A)
- Project submission application form for initial review (C)
- Protocol (A)
- Forwarding letter/approval from concerned scientific review board - A
- Amendments to protocol (if any suggested by the SRB) (A)
- Informed consent document: In English and Kannada/Malayalam (if applicable), along with back translations in English (in case of regulated clinical trials). (A)
- Patient information sheet in English and Kannada/Malayalam (if applicable) along with back translations (in case of regulated clinical trials). (A)
- Translation and Back translation certificates (if applicable) (C)
- Amendments to the Informed consent form (if any) (A)
- Case record form (A)
- Recruitment procedures including advertisement, notices, letters to doctors, permission letters from hospital (if and whichever applicable) (C)
- Regulatory permissions (DCGI Approval, etc; whenever applicable) (C)

- Undertaking to DCGI (If applicable) (C)
 - Administrative sanctions from the Head of the institution or MoU in case of studies involving collaborative work or in case of sending samples to laboratories of other centres or institutions (A)
 - Ministry of External Affairs permission to send samples out of country (if applicable) (A)
 - Curriculum vitae of all investigators (C)
 - Training certificates [C, A(if applicable)]
 - GCP training certificate of the Principal investigator (within last 5 years) (C)
 - Certification in Research Methodology of the Principal Investigator (C)
 - List of on-going research projects undertaken by the Principal Investigator [C, A (if applicable)]
 - Drug/device brochure (C)
 - Details of funding and fund allocation [C, A (if applicable)]
 - Clinical trial agreement with sponsors, investigators, and head of the institution (C)
 - Insurance policy (policy details) of the participants indicating conditions of risk coverage, data of commencement and expiry of risk coverage. (C)
 - Indemnity policy with details. (C)
 - Ethics Committee clearance of other centers (if applicable) [C, A (if applicable)]
 - Institutional Stem cell Research Committee approval (if applicable)
 - Documentation of clinical trial registration (if available)
 - Processing fee payment receipt (*See Guidelines for investigators*) (C)
- Note: C = Regulated clinical trial; A = All others**

4.1.2.3 Complete the submission process:

- The Secretariat will check the submission checklist for completion
- Stamp the receiving date on the first page/last page of the covering letter and initial it.

- Make a photocopy of the completed document receipt form Ann04/SOP06/v2 and return the original copy of the Ann04/SOP06/v2 to the applicants for their records.
- Keep the copies of the submitted documents with original signatures in the protocol “Submission” file.
- Number the project file as YEC-1/ YEAR/ NUMBER. This number is quoted for all future communications concerning the protocol.

4.1.2.4 Dispatch and store received documents:

- The Secretariat will make photocopies of the protocols only if the reviewers assigned request for hard copies. Otherwise all the document communications will be done through the official email of YEC-1 ethcom@yenepoya.edu.in
- The Secretariat will ensure the protocol attaches the checklist Ann2A/SOP 06/v2 or Ann2B/SOP06/v2.
- The Secretariat will file all assessment forms as determined by the type of submission and type of review.
- The documents will be despatched for review to the reviewers by email within 4 calendar days of receiving the submission.
- The Secretariat will follow the colour code for files for various types of research protocols

Green for funded projects

Yellow for dissertations and theses

Blue for faculty projects

Box files for clinical trials

4.1.3 Resubmission of protocol with corrections and amendment of protocols:

4.1.3.1 All resubmissions will be made as hard copy submitted to the YEC-1 Secretariat along with a covering letter and a soft copy which emailed to ethcom@yenepoya.edu.in

4.1.3.2 The Secretariat will verify the completeness of the documents.

4.1.3.3 In case of minor changes/amendments, the same version is submitted with changes highlighted

- 4.1.3.4 In case of major changes or amendments, the resubmission is numbered as version 2 (written as v2 in the header).
- 4.1.3.5 The protocol related documents which do contain changes/amendments which are already submitted and approved by the YEC-1 are not required to be submitted again.
- 4.1.3.6 The Secretariat will submit the documents to the Member-Secretary/Jt Secretary.
- 4.1.3.7 The Member-Secretary/Jt Secretary will decide the review process under which the resubmissions and amended protocols will be categorised.
- 4.1.3.8 The protocol management will follow the relevant SOPs depending on the type of review process
- Full review: SOP7A/v2
 - Expedited review: SOP7B/v2
- 4.1.4 **Annual continuing review of approved protocols, amended protocols and related documents/ study completion documents/termination reports, SAE reports, protocol deviation:**
- 4.1.4.1 The YEC-1 will receive one soft copy and one hard copy of the Continuing Review Report, Amended Protocols and related documents, Study completion/ termination, SAE report, protocol deviations in the prescribed format as given in the applicable SOPs.
- 4.1.5 ***Processing Fees for YEC-1 review***
- The fees for reviewing various categories of research study proposals in Indian Rupees (INR); non-refundable are as given in the following table:

Sr No	Category of review	Pharma industry sponsored Research	Govt sponsored/ NGO Research	Academic or Investigator initiated Research
1.	New study protocol	Rs. 25,000 /-	Rs. 20,000 /-	Nil
2.	Continuing review (per review)	Rs. 15,000 /-	Rs.10,000 /-	Nil
3.	Protocol Amendment (per amendment review) (if applicable)	Rs. 15,000 /-	Rs. 10,000 /-	Nil

5. Reference to other applicable SOPs

- 5.1 SOP06/v2: Management of Research Study Protocol and Study Related Documents Submitted for Ethics Review
- 5.2 SOP7A/v2: Full-Board Review of Research Study Protocols
- 5.3 SOP09/v2: Review of Amended Protocol, Protocol-related Documents and Resubmitted protocol
- 5.4 SOP15/v2: Request for Waiver of Written Informed Consent and Waiver of Consent

6. Annexures:

- 6.1 Ann1A/SOP06/v2: Project submission application form for initial review for drug trials and other regulatory studies (Industry and Government sponsored studies).
- 6.2 Ann1B/SOP06/v2: Project submission application form for initial review for academic (non-regulatory) studies.
- 6.3 Ann2A/SOP06/v2: Checklist protocol submission for initial review of regulated clinical trials
- 6.4 Ann2B/SOP06/v2: Checklist protocol submission for initial review of academic (non-regulated) studies
- 6.5 Ann03/SOP06/v2: Duty Delegation Log of Study team
- 6.6 Ann04/SOP06/v2: Document Receipt Form

Ann1A/SOP 06/v2

Project Submission Application Form for Initial Review for Drug Trials and Other Regulatory Studies (Industry and Government sponsored studies)

- Please fill in the details in legible hand writing
- Tick ✓ in the box for the appropriate answer
- Tick/ Write NA if question is not applicable

YEC-1 Protocol No.:					
Title of the protocol:					
	Name	Designation and qualification	Department and Institution	Roles and responsibility*	Signature
Principal Investigator					
Co-Investigator					

Co-Investigator					
Co-Investigator					
Co-Investigator					
Co-Investigator					
Co-ordinator					
Co-ordinator					

* Roles and responsibilities of investigators: choose the appropriate codes (A to T) below and write them against their name in the appropriate column above.

- | | |
|---|--|
| <ul style="list-style-type: none"> A. Concept B. Design C. Screening of patients D. Selection and recruitment of study participants E. Informed consent F. Selection & Recruitment of patients G. Laboratory investigations H. Laboratory report interpretation I. Treatment decision J. Patient evaluation K. SAE evaluation and reporting | <ul style="list-style-type: none"> L. Examination of patients on follow-up M. Data collection and monitoring of data N. Interpretation of data O. Statistical analysis & Interpretation P. Maintaining patients file and master file of project Q. Drafting final report R. Submission of final report to funding agency and YEC-1 S. Publication T. Any other, please specify |
|---|--|

(If additional collaborators attach details and letter of Consent by collaborator(s) on a separate page)
Please attach brief curriculum vitae of the study team members (principal investigator, co-investigator, study coordinator)

Attached

Non-sponsored (Investigator Initiated) study

Sponsored study				
Sponsor Information :				
1	Indian	State Govt.	Central Govt.	Private
2	International	Govt.	Private	UN Agency
3	Industry	National	Multinational	
4	Contact address			
5	Indian contact address (For international sponsors)			
Budget information				
1	Total Budget: Rs.			
2	Please give details of allocation of budget in an attachment. Attached <input type="checkbox"/>			
3	Research Fund will be deposited in: If other, please specify			
Details of the study				
Type of study	Epidemiological		Animal study	
	Basic Science		Any other: Specify:	
Number of centres	Single centre		Multicentre:	
If multi-centric:	Number of centres In India Global:		Names and countries of centres:	
Clinical Trials:				
1	Nature of trial	Medicine		Devices
		Vaccine		Indian system of Medicine
		Any other: Specify:		Not applicable
2	Approved	Yes		No
		If Approved:		
		In India		UK/Europe
		USA		NA
		Other countries: Specify:		

3	Route	Does it involve change in route of administration	Yes # No Not applicable
		If Yes #, Whether DCGI/other regulatory authority's permission obtained	Yes * No ** Not applicable
		If yes * Date of Permission	
		If No **, Whether applied of permission	Yes/No Not applicable
4	New investigational drug	Yes No Not applicable	If yes, IND No.
		a) Investigator's Brochure submitted	Yes No NA
		b) <i>In vitro</i> studies data	Yes No NA
		c) Preclinical Studies done	Yes No NA
		Clinical Study Phase	I II III IV
		To submit package insert in case test drug is already marketed in India	Attached Not attached
		Are you aware if this study/similar study is being done elsewhere? If yes give details	Yes: No
Whether DCGI's permission for testing IND obtained? If yes, Date of permission	Yes No		
Whether DCGI's permission for testing IND is applied for?	Yes No		
For Ayurvedic or herbal formulations, is a copy of the marketing/ manufacturing license issued by the FDA to the company submitted?	Yes No Not applicable		
Protocol of proposal – Introduction, review of literature, aim(s) & objectives, justification for study, methodology describing the potential risks & benefits, outcome measures, statistical analysis and whether it is of national significance with rationale (Submit as attachment)			

5	Research participants			
	Sample Size : Number of research participants at this centre : Number of research participants at other sites in India : Total number of research participants at all sites (globally):			
	Duration of study No. of visits :			
	Will research participants from both genders be recruited	Yes	No	NA
	Inclusion / exclusion criteria given	Yes	No	NA
	Type of research participants:			
	Volunteers	Yes	No	NA
	Patients	Yes	No	NA
	Vulnerable participants	Yes	No	NA
	Pregnant women	Yes	No	NA
	Elderly	Yes	No	NA
	Mentally challenged	Yes	No	NA
	Fetus	Yes	No	NA
	Illiterate	Yes	No	NA
	Handicapped	Yes	No	NA
	Children	Yes	No	NA
	Captives	Yes	No	NA
	Terminally ill	Yes	No	NA
	Seriously ill	Yes	No	NA
	Economically or socially backward	Yes	No	NA
Dependent staff	Yes	No	NA	
Institutionalized students	Yes	No	NA	
Employees	Yes	No	NA	
HIV	Yes	No	NA	
Any other	Yes	No	NA	

6	Privacy and confidentiality			
	Direct identifiers	Yes	No	NA
	Indirect identifiers (coded)	Yes	No	NA
	Completely anonymized (delinked)	Yes	No	NA
7	Use of biological/hazardous materials			
	Fetal tissue or abortus	Yes	No	NA
	Human organs or body fluids	Yes	No	NA
	Recombinant /gene therapy If yes: DBT approval obtained	Yes	No	NA
	Pre-existing/stored/left over samples	Yes	No	NA
	Collection of banking/future research	Yes	No	NA
	Collection for banking/future research	Yes	No	NA
	Use of ionizing radiation/radioisotopes If yes, has Bhabha Atomic Research Centre (BARC) approval for radioactive isotopes been obtained?	Yes Yes	No No	NA NA
	Use of Infectious/ bio hazardous specimens	Yes	No	NA
	Proper disposal of material	Yes	No	NA
8	Will any sample collected from the patients be sent abroad?	Yes	No	NA
	<p>If yes Sample will be sent abroad because (Tick appropriate option): Facility not available in India Facility in India inaccessible Facility available but not being accessed If so, reasons..... Lab. Address:</p>			
	<p>If no, Test on samples will be carried out (tick appropriate option): In institution Outside institution If outside institution, Address: ____ Specify with details of collaborators</p>			
9.	Is the proposal being submitted for clearance from Health Ministry's Screening Committee (HMSC) for International collaboration? (required in case of studies involving collaborations with foreign Laboratory/ Clinic/Institution)	Yes	No	NA
10	In case of studies involving collaborations with other Indian or foreign Laboratory/ Clinic/Institution has administrative sanction from the Dean obtained/ applied for? If yes, details:	Yes	No	NA
	Memorandum of Understanding: If yes, details	Yes	No	NA
	Material Transfer Agreement If yes, details	Yes	No	NA

11	Consent form & participation information sheet	Yes	No	NA
<p>Tick which elements are included:</p> <ul style="list-style-type: none"> Simple language Alternatives to participation Statement that study involves research Confidentiality of records Sponsor of study Contact information Purpose and procedures Statement that consent is voluntary Risks & Discomforts Right to withdraw Benefits Compensation for study related injuries Compensation for participation Benefits, if any, on future commercialization Consent for future use of biological material If written consent will not be obtained, give reasons: Whether applied for waiver of Consent: 				
<p>Who will obtain consent?</p> <ul style="list-style-type: none"> PI/Co-PI Nurse/Counselor Research staff Any other, specify 				
12	Will any advertising be done for recruitment of research participants? (posters, flyers, brochure, websites – if so kindly attach a copy)	Yes	No	NA
13	Risks & Benefits:			
Is the risk reasonable compared to the anticipated benefits to research participants / community / country?		Yes	No	NA
<p>Is there physical / social / psychological risk / discomfort? If Yes,</p> <ul style="list-style-type: none"> • Minimal or no risk • More than minimum risk • High risk 		Yes	No	NA
<p>Is there a benefit To the research participants?</p> <ul style="list-style-type: none"> • Direct • Indirect 		Yes	No	NA
Benefit to the society		Yes	No	NA
14	Data Monitoring			
Is there a data & safety monitoring committee/ Board (DSMB)?		Yes	No	NA
Is there a plan for reporting of adverse events?		Yes	No	NA
If Yes, reporting is done to :				

	Sponsor YEC-1 DSMB	Yes	No	NA
	Is there a plan for interim analysis of data?	Yes	No	NA
	Are there plans for storage and maintenance of all trial database? If Yes, for how long?	Yes	No	NA
15	Is there compensation for participation If Yes, (tick appropriate) Monetary In kind Specify amount and type:	Yes	No	NA
16	Is there compensation for injury? If Yes, (tick appropriate) by Sponsor by Investigator by insurance by any other company	Yes	No	NA
17	Do you have any conflict of interest in the present study? (financial/non financial) If Yes, specify	Yes	No	NA
18	Number of protocols handled by the PI at present including current Status of ongoing studies approved by IEC and carried out by the Principal Investigator. (Information to be given: whether study is initiated, no. of approved research participants, no. of research participants enrolled, no. of active research participants, no. of research participants who have completed the study and total duration of the study. Describe briefly	Yes	No	NA
19	Current Brief Curriculum Vitae (signed and dated copy) of the study team members- principal investigator, co-investigator and study coordinator (Information required: age, designation and department, educational qualification, previous research experience in last five years) (Information about GCP training of PI and co investigator)	Yes	No	NA
20	Training certificates of principal investigator and coordinators (mandatory only for drug and device trials not for observational studies)	Yes	No	NA
21	Is the trial registered with Clinical Trial Registry? (mandatory only for drug trials) Clinical Trial Registry of India(CTRI)/ any other WHO platform registry Registration number: If not registered, state the reason	Yes	No	NA

Statement of Compliance:

We hereby declare that the information given above is true and that we will comply with the guidelines mentioned in the Schedule Y [Drugs and Cosmetic Act 1940; amendment 20th January 2005, 30th January 2013, 8th February 2013 and any other recent notification/s from CDSCO (updated as applicable)], Ethical Guidelines for Biomedical Research on Human Participants by Indian Council of Medical Research (2006), Indian GCP Guidelines (2001) and the International Conference on Harmonisation - Good Clinical Practices (ICH-GCP) Guidelines (1996) while conducting the research study.

We also ensure that Principal Investigator / Institution will pay for treatment and / or compensation if study related injury occurred due to protocol violation by PI / study team.

Signature of Principal Investigator with date:

Signature/s of Co-investigators with date:

- 1.
- 2.
- 3.
- 4.
- 5.

Signature of coordinator:

- 1.
- 2.

Forwarded by Heads of Department(s)

Signature/s with date of Heads of Department(s):

Stamp/Seal of the Department(s)

Ann1B/SOP06/v2

**Project Submission Application Form for Initial Review for Academic (non- regulatory)
Studies**

Please fill in the details in legible hand writing. Incomplete forms are likely to be rejected.
Tick in the box for the appropriate answer/ Write NA if question is not applicable

YEC-1 Protocol No. (to be filled by YEC-1 Secretariat at time of submission)			
Protocol title:			
Details of research study team	Name	Designation	Affiliation
Principal Investigator			
Co-Investigator			
Co-Investigator			
Co-Investigator			
<i>If additional collaborators attach details and letter of consent by the collaborator (s) on a separate page</i>			
Study is sponsored:		Yes / No	
If sponsored Total Budget: Rs. _____ From where is the study being funded a) Research fund is being utilized from in-house funding authority b) External funding agency (specify):			
Type of study: (tick whichever is applicable) a) Prospective / Retrospective / Cross-sectional b) Observational / Interventional If interventional, does the study involve Testing of a new drug? Yes / No Any deviation from routine/standard of care practices? Yes / No If yes to any of above questions, please provide details			
2. What is the type of intervention being researched? (tick whichever is applicable) a. Drug b. Alternative medicine c. Medical device d. New technique (surgical, OT, PT, etc)			

<p>e, New diagnostic kit/method</p> <p>f. Other (please specify):</p> <p>g. Is the test/drug/device marketed in India? Yes / No</p> <p>If yes to any of the above questions please provide relevant regulatory authority permissions (wherever applicable). Also please attach a copy of the package/product insert.</p>
<p>3. Subject selection:</p> <p>a. Number of subjects to be selected at this centre: If multicentric: Total no. of centres: Total no. of subjects from all centres:</p> <p>b. Vulnerable subjects: Yes / No (tick whichever is applicable)</p> <p>c. Pregnant women / Illiterate / Seriously/terminally ill / Children / Neonates / Mentally challenged / Elderly / Physically challenged / Economic/social backwardness / Institutional employees / Students / Others (please specify)</p>
<p>4. Does the study involve use of:</p> <p>a. Fetal tissue or abortus Yes / No</p> <p>b. Organs or body fluids Yes / No</p> <p>c. Gene therapy/genomics/proteomics Yes / No If yes for gene therapy, then please attach copy of permission from Genetic Engineering Advisory Committee (GEAC)</p> <p>d. Ionizing radiation / Radioisotopes Yes / No If yes, please submit a copy of Bhabha Atomic Research Centre (BARC) Permission.</p> <p>e. Infectious / biohazardous specimens Yes / No</p> <p>f. Will pre-existing / stored / left over samples be used Yes / No</p> <p>g. Will samples be kept for banking / future research purpose Yes / No</p> <p>h. Will any sample be sent abroad Yes / No If yes, please submit a copy of Director General of Foreign Trade (DGFT) permission</p> <p>i. Is there any collaboration with an external institution, laboratory or clinic (either domestic or foreign) Yes / No</p> <p>a. If yes, please attach copy of MoU between YU and that organization.</p> <p>b. If yes for foreign collaboration, please submit a copy of Health Ministry Screening Committee (HMSC) approval <i>or any other funding agency requirements (as applicable).</i></p>
<p>5. Will any advertising be done for recruitment of Subjects? (Posters, flyers, brochures, etc) If yes, kindly attach a copy for YEC-1 review</p>
<p>6. Is there compensation for participation (travelling allowance)? If yes, then Monetary / Kind If monetary, then specify amount: If kind, then provide details:</p>
<p>7. Are there any arrangements for compensation / treatment of trial related injury? If yes, then who will provide: Sponsor / Insurance company / Investigator / Others Please provide relevant copies</p>

8. Do you (or your PG guide) have any conflict of interest in the present study? (financial / non – financial/ any other) Yes / No If yes, specify
9. Is any other department involved in participant recruitment / investigation, but not co-investigators or collaborators? Yes / No If yes, give details: Attach relevant copy of other department with HOD signature

We hereby declare the information given above is true. A copy of the study report will be submitted at the end of the study.

Signature of Principal Investigator:

Signatures of Guide/Co- investigators:

Signatures (with seals) of forwarding authorities (as predetermined by YU):

Ann2A/SOP06/v2

**Check List for Protocol Submission to Yenepoya Ethics Committee - 1
for initial review of regulated clinical trials**

Check List of Documents for Protocol Submission to the Yenepoya Ethics Committee - 1 to be filled in by the study team

(Tick accordingly; Items marked * are compulsory documents and have to be submitted)

Sl No	Document	Yes	No	If pending, likely date of submission	NA
1.	*Project submission application form duly filled				
	a. Covering Letter				
	b. Project proposal – 3 hard copy				
	c. Project proposal – soft copy sent by e-mail to ethcom@yenepoya.edu.in				
	d. CV of ALL Investigators				
	e. Fee for review				
2	Approval of Scientific Review Board (SRB)				
3	*Letter to Member-Secretary requesting ethical clearance				
4	*Summary of protocol (in not more than 500 words)				
5	*Protocol				
6	*Informed consent document in English				
7	*Informed consent documents in Regional languages (Total No:-)				
8	Back translation of Informed Consent Documents (if available)				
9	Translation and Back translation certificates (if available)				
10	*Case Record Form				
11	*Research participants recruitment procedures: advertisement, notices (If applicable)				
12	*Patient instruction card, identity card, diary etc.				
13	a. *Research participants Questionnaire/s (If applicable)				
	b. Research participants confidentiality statement				

14	*Investigator brochure				
15	*Insurance certificate and policy				
16	*Investigator's undertaking to DCG(I)				
17	DCG(I) approval [if DCGI approval is awaited, the same is mentioned in the covering letter to the YEC-1]				
18	*Clinical Trial Agreement for drug trial / Memorandum Of Understanding / Copy of clinical trial protocol Material Transfer Agreement (MTA), as applicable, for collaborator & Govt sponsored trials (draft if final not ready)				
19	FDA marketing/manufacturing license for herbal formulations/ nutraceuticals				
20	Bhabha Atomic Research Centre (BARC) approval in case study involves use of radioisotopes/ ionizing radiations				
21	Genetic Engineering Advisory Committee (GEAC) approval in case study involves use of gene therapy				
22	a) Administrative sanction from the Head of the Institution in case of collaborative studies with other institutions / foreign agencies (one copy) Or Memorandum of Understanding (as applicable)				
	b) Administrative sanction from the Head of the Institution for the samples to be sent to outside institution (one copy) Or Material Transfer Agreement (as applicable)				
23	*Budget Sheet for the Proposed Study (Format for budget sheet stated below)@				
24	*Signed and dated brief current curriculum vitae of the study team members (principal investigator, co-investigator, study co-ordinator) (one copy only)				
25	*Ethics Committee clearance of other centres (Total No _____)				
26	*Log of delegation of responsibility of the study team members - Sample Format Enclosed)				
27	*Document Receipt Form (one copy only)				
28	*Current Status of Ongoing Studies approved by IEC and IEC conducted by principal investigator (information may be				

	submitted separately)				
29	Documentation of clinical trial registration (in Clinical Trial Registry of India) / any other WHO platform registry (whenever applicable)				
30	*GCP training certificates of principal investigator, co investigator/s, study co-ordinator/s for interventional clinical trial sponsored by pharmaceuticals companies of training taken in last 5 years (one copy only)				
31	Any other Documents submitted				

Budget:

1	Title of the Project:	
2	Name of Principal Investigator (PI)	
3	Designation and address of the PI	
4	Names of Co-investigators with department/institution:	
5	Source of funding (tick whichever is applicable) a. Government: b. In-house c. Private Foundation: d. Non profit agency/trust funded e. Pharma./ industry sponsored f. Other: g. No funding required	
6	Address, phone, fax, email of sponsor with the name of the contact person	
7	Total Budget for the entire project in Rs.	
8	Duration of the Project in months	
9	Proposed date of starting the project	
10	Direct payments to investigators, if any	
11	Other benefits to investigator/department/institution	
12	Conflict of Interests, if any	

Name of the PI with signature and date:

Ann2B/SOP06/v2

Checklist for protocol submission for initial review of academic (non-regulated) studies

To be filled by PI/PG Student and checked by YEC-1 Secretariat

Note: Incomplete protocol packages will not be accepted and will not be assigned a number till document package is complete as per checklist

No	Document	Yes	No	Reason for "No"	YEC-1 Secretariat to confirm
1	Letter to Member-Secretary Yenepoya Ethics Committee - 1 requesting ethical clearance				
2	Project proposal – soft copy sent by e-mail to ethcom@yenepoya.edu.in <i>(Please note that there should be no discrepancy between the hard copy and the soft copy submitted)</i>				
3	Brief signed copy of Curriculum Vitae (CV) of ALL Investigators (including PI, Co-PI, Guide) not more than two pages focusing on research activities and research training				
4	Fee for review (not applicable for YU students/faculty)	--	--	---	
5	Approval of Scientific Review Board (SRB) <i>(Please note that the Principal Investigator (PI) and the guides are responsible to ensure that there is no discrepancy between the hard copy and the soft copy of the protocol submitted to the YEC-1 and that approved by the SRB)</i>				
6	Detailed Protocol				
	a Title				
	b Objectives and hypothesis (research question)				
	c Background				
	d Justification / Need for the study				
	e Review of literature				
	f Detailed methodology				
	i Study design: Prospective/Retrospective Observational/Interventional/etc				
	ii Site (s) of study <i>(Attach permission letters from concerned authorities if the study is to be conducted outside the ambit of Yenepoya deemed to be University or provide a copy of the MoU)</i>				
	iii Sample size: (with justification)				

	iv	Sampling technique				
	v	Inclusion criteria (if any)				
	vi	Exclusion criteria (if any)				
	vii	Randomization (if any)				
	viii	Details of clinical examination (if any) <i>(attach anonymised clinical data collection pro forma)</i>				
	ix	Details of questionnaire (if any) <i>(attach anonymised questionnaire wherever necessary with translation)</i>				
	x	Details on discontinuation/withdrawal of participant from study criteria (Example: Occurrence of complications or non compliance by the participant)				
	xi	Vulnerable participant (Example: Children, pregnant women, Psychiatric illness etc..) (if yes, provide justification)				
	xii	Use of placebo (if yes, provide justification)				
	xiii	Details of investigations (if any) and how the sample will be obtained and processed				
	xiv	Whether samples will be sent outside the institution /processed abroad <i>(Provide permission letter from concerned authority)</i>				
	xv	Details on how samples will be destroyed				
	xvi	Details on whether the data/samples/tissues are likely to be shared				
	xvi i	Details of data tabulation and statistical methods to be employed				
	f	Time line				
	g	Budget/Expenditure and how the finances will be met (Name of the sponsor, budget allocated and justification)				
	h	Expected outcome/benefit to participants, investigators, institution and society				
7.	Ethical Issues					
	a	Recruitment of participants will start only after the ethical clearance				
	b.	Protection of vulnerable participants				
	c.	Disposal of tissue samples				
	d.	Maintenance of privacy of participants				

	e.	Maintenance of confidentiality of data				
	f.	Sharing of samples/data				
	g.	Compensation to participants				
	h.	Ensuring standard of care to participants				
	i.	Redacting of MRD files/Radiographic material/histopathology slides/blood and tissue samples				
8	Informed consent document in English					
	a.	Is the language simple and clear such that an eight standard student (English or vernacular) will find easy to understand				
	b.	Whether contact person details are provided in the ICF				
	c.	Whether the PG/PI has assured privacy of participants & confidentiality				
	d.	Has the PG/PI mentioned compensation for time taken to participate				
	e.	Has the PG/PI mentioned how study-related injuries will be managed				
	f.	Has the PG/PI mentioned how such study – related injuries will be Compensated				
	g.	Has the PG/PI made specific mention of whether data will be shared and how				
	h.	Has the PG/PI taken consent for publication				
	i.	In case a participant is illiterate, has the PG/PI made provision for an independent witness to countersign				
9	Informed consent documents in Regional languages					
10	Participant Information Sheet on a separate sheet (English & Regional language)					
11	Any other documents submitted (please fill reverse)					

DECLARATION BY THE PG STUDENT AND THE GUIDE /PRINCIPAL INVESTIGATOR

I, Dr. (Name of PG/PI) and my guide, Dr. (Name of the Guide) do hereby declare that this study will be carried out by the PG student and supervised by the guide upholding the concepts in the Declaration of Helsinki and simultaneously abiding by the latest ICMR guidelines.

Place:

Sign of PI:

Date:

Sign & Seal of the Guide:

Ann03/SOP06/v2

Delegation of Responsibilities of Study team

YEC-1 Protocol No.		
Study title:		
Name	Role	No.
	Principal Investigator	1
	Co-Investigator	2
	Co-Investigator	3
	Co-investigator	4
	Co-Investigator	5
	Co-investigator	6
	Study co-ordinator *	7
	Study co-ordinator *	8
	Laboratory Technician	9
Please fill if more members on team		

(Please place tick marks against assigned duties for each member in the following table)

Code	Tasks	Role played by each study team member												
		1	2	3	4	5	6	7	8	9	10			
A	All relevant documents pertaining to protect blinding													
B	Research participants' selection/ screening													
C	Obtain informed consent													
D	Evaluate inclusion/ exclusion criteria													
E	Conduct the visit assessments													
F	Physical examination													
G	Complete the source documents													
H	Complete Case Record Form													
I	Final review and sign Case Record Form													
J	Collect laboratory safety test samples													
K	Processing of blood samples													
L	Preparing aliquots & keeping a track of the samples sent													
M	Review & sign of the lab reports													
N	Receive the study drug, document drug dispensing, storage & accountability													

O	Person to whom research participants should contact in case of adverse event													
P	Report all serious adverse events													
Q	Follow up of Serious Adverse Event													
R	Maintaining study site master file													
S	In-charge of inventory & supplies													
T	Archiving of study documents													
U	Resolution of queries													
V	Overall coordination & supervision													

**Ann04/SOP065/v2
Receipt for Submitted protocol**

Protocol No.		
Received date:		
Submitted date:		
Protocol title		
Principal Investigator Name, Designation and Affiliation		
Communication with YEC-1	e-mail address: Phone: Fax:	
For office use only		
Documents submitted (tick whichever is applicable)	Complete / Incomplete / Will submit on	
Late documents submitted	Name of the document	Recd date
	Final signed clinical trial agreement	
	Informed consent form (English + local language)	
	Study budget	
	DCGI	
	CTRI	
	GCP training certificate	
	Other sites EC permission (if available)	
Other documents (if any)		
Received by: (Name and signature)		
Date of document receipt:		

Note: Please bring this receipt with you when you visit the YEC-1 Secretariat.

7. Flowchart:

No.	Activity	Responsibility
1	Receive Submitted Packages	YEC-1 Secretariat
2	Initial Review Application	YEC-1 Secretariat
3	Resubmission of Protocols with Corrections	YEC-1 Secretariat
4	Protocol Amendments	YEC-1 Secretariat
5	Annual Continuing Review of Approved Protocols	YEC-1 Secretariat
6	Protocol Completion	YEC-1 Secretariat